

**PATENTS ONLY**

To the Honorable Assistant Commissioner for Patents: Please record the attached original documents or copy thereof

1. Name of conveying party):  
Alberto A. Gabizon

Add'l names of conveying parties attached?  
☐ Yes ☒ No

3. Nature of conveyance: ☒ Assignment  
☐ Merger ☐ Security Agreement ☐ Other  
☐ Change of Name ☐ Reassignment

4. Date of execution: 19 June 2000

2. Name/address of receiving party:  
Hadasit Medical Research Services  
and Development, Inc.

Kiryat Hadassah  
P.O.B. 12000  
Jerusalem 91120, Israel

Add'l names of receiving parties  
attached? ☐ Yes ☒ No

5. Application number(s) and/or patent number(s):

If this document is being filed with a new application, the date of signature  
by the first named inventor was: \_\_\_\_\_.

A. Patent Application No.(s)  
09/555,674 filed 2 June 2000

B. Patent No.(s)

Additional numbers attached: ☐ Yes ☒ No

6. Name and address of party to whom  
correspondence concerning document  
should be mailed:

**Iota Pi Law Group**  
**P.O. Box 60850**  
**Palo Alto, CA 94306**  
**(650) 324-0880**

7. Total No. of applications and  
patents involved:  
one (1)

8. Total fee (37 CFR \$3.41): \$40.00  
☒ Enclosed is check for \$40.00

9. Total number of pages, including  
cover sheet, attachments and  
document: 4

**DO NOT USE THIS SPACE**

10. Statement and signature:

*To the best of my knowledge and belief, the foregoing information  
is true and correct and any attached copy is a true copy of the  
original document.*

LeeAnn Gorthey  
Name of Person Signing

LeeAnn Gorthey  
Signature

7-31-00  
Date

COPY

**PATENTS ONLY**

To the Honorable Assistant Commissioner for Patents: Please record the attached original documents or copy thereof

1. Name of conveying party): Eliezer Kedar Yechezkel Barenholz  Add'l names of conveying parties attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2. Name/address of receiving party:  Yissum Research Development Company of the Hebrew University of Jerusalem  46 Jabotinsky Street Jerusalem 91042, Israel  Add'l names of receiving parties attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Other <input type="checkbox"/> Change of Name <input type="checkbox"/> Reassignment	
4. Date of execution: <u>22 June 2000 and</u> <u>20 June 2000, respectively</u>	

5. Application number(s) and/or patent number(s):  
  
If this document is being filed with a new application, the date of signature by the first named inventor was: \_\_\_\_\_.

A. Patent Application No.(s) 09/555,674 filed 2 June 2000	B. Patent No.(s)
--	------------------

Additional numbers attached: ☐ Yes ☒ No

6. Name and address of party to whom correspondence concerning document should be mailed:  Iota Pi Law Group P.O. Box 60850 Palo Alto, CA 94306 (650) 324-0880	7. Total No. of applications and patents involved: <u>one (1)</u>
	8. Total fee (37 CFR \$3.41): <u>\$40.00</u> <input checked="" type="checkbox"/> Enclosed is check for \$40.00
	9. Total number of pages, including cover sheet, attachments and document: <u>4</u>

DO NOT USE THIS SPACE

10. Statement and signature:  
  
*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.*

LeeAnn Gorthey  
Name of Person Signing

LeeAnn Gorthey  
Signature

7-31-00  
Date

**COPY**

#4

Attorney Docket No.: 9325-0007.10  
Applicant: Alberto A. Gabizon et al.  
Serial No.: 09/555,674  
Filing Date: June 2, 2000  
For: COMBINED CHEMO-IMMUNOTHERAPY WITH LIPOSOMAL DRUGS AND CYTOKINES

Small Entity Statement Under  
37 CFR 1.9(f) and 1.27(c) - Small Business Concern

I hereby declare that I am: \*

- ☐ The owner of the small business concern identified below:  
☒ An official of the small business concern empowered to act on behalf of the concern identified below:

Name of Concern: Hadasit Medical Research Services and Development Ltd.

Address of Concern: Kiryat Hadassah, P.O.B. 12000, Jerusalem 91120, Israel

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR §121.12, and reproduced in 37 CFR §1.9(d), for purposes of paying reduced fees under 35 U.S.C. §41 in that the number of employees, including those of its affiliates, does not exceed 500 persons and the concern has not assigned, granted, conveyed, or licensed, and is under no obligation under contract or law to assign, grant, convey, or licenses, any rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern or a nonprofit organization under this section. For this section, concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both. The number of employees of the business concern is the average over the fiscal year of the persons employed during each of the pay periods of the fiscal year. Employees are those persons employed on a full-time, part-time or temporary basis during the previous fiscal year of the concern.

I hereby declare that rights under contract or law in the above-identified application have been conveyed to and remain with the small business concern identified above.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR §1.9(d) or by any concern which would not qualify as an independent inventor under 37 CFR §1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR §1.9(d) or a nonprofit organization under 37 CFR §1.9(e).

NOTE: Separate statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR §1.27).

Name: Yisum Research Development Company of the Hebrew University of Jerusalem

Address: Jabotinsky Street 46, Jerusalem 91042, Israel

☐ individual    ☒ small business concern    ☐ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 CFR \$1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. \$1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this statement is directed.

**RAPHAEL HOFSTEIN PH.D.**

MANAGING DIRECTOR

HADASIT MEDICAL RESEARCH

SERVICE & DEVELOPMENT LTD.

NAME OF PERSON SIGNING: \_\_\_\_\_

TITLE OF PERSON SIGNING: \_\_\_\_\_

ADDRESS OF PERSON SIGNING: \_\_\_\_\_

הדאסיט  
hadasit  
medical research services  
& development ltd.

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

5/6/2000

Attorney Docket No.: 9325-0007.10

Applicant: Alberto A. Gabizon et al.

Serial No.: 09/555,674

Filing Date: June 2, 2000

For: COMBINED CHEMO-IMMUNOTHERAPY WITH LIPOSOMAL DRUGS AND CYTOKINES

Small Entity Statement Under  
37 CFR 1.9(f) and 1.27(c) - Small Business Concern

I hereby declare that I am: \*

- ☐ The owner of the small business concern identified below:
- ☒ An official of the small business concern empowered to act on behalf of the concern identified below:

Name of Concern: Yissum Research Development Company  
of the Hebrew University of Jerusalem

Address of Concern: Jabotinsky Street 46,  
Jerusalem 91042, Israel

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR §121.12, and reproduced in 37 CFR §1.9(d), for purposes of paying reduced fees under 35 U.S.C. §41 in that the number of employees, including those of its affiliates, does not exceed 500 persons and the concern has not assigned, granted, conveyed, or licensed, and is under no obligation under contract or law to assign, grant, convey, or licenses, any rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern or a nonprofit organization under this section. For this section, concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both. The number of employees of the business concern is the average over the fiscal year of the persons employed during each of the pay periods of the fiscal year. Employees are those persons employed on a full-time, part-time or temporary basis during the previous fiscal year of the concern.

I hereby declare that rights under contract or law in the above-identified application have been conveyed to and remain with the small business concern identified above.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR §1.9(d) or by any concern which would not qualify as an independent inventor under 37 CFR §1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR §1.9(d) or a nonprofit organization under 37 CFR §1.9(e).

NOTE: Separate statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR §1.27).

Name: Hadasit Medical Research Services and Development Ltd.

Address: Kiryat Hadassah, P.O.B. 12000, Jerusalem 91120, Israel

☐ individual    ☒ small business concern    ☐ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 CFR \$1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. \$1001, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this statement is directed.

NAME OF PERSON SIGNING: Mordechai Perlmutter

TITLE OF PERSON SIGNING: Managing Director & CEO

ADDRESS OF PERSON SIGNING: 46 Jabotinsky St., POB 4279, Jerusalem 91042, ISRAEL

Signature: \_\_\_\_\_

Date: JUNE 19, 2000

000080" 42955360

**COMBINED DECLARATION AND POWER OF ATTORNEY**  
**includes Reference to PCT International Applications)**

ATTORNEY'S DOCKET NUMBER  
**9325-0007.10**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**COMBINED CHEMO-IMMUNOTHERAPY WITH LIPOSOMAL DRUGS AND CYTOKINES**

the specification of which (check only one item below):

- ☐ is attached hereto.  
☐ was filed as United States application Serial No. \_\_\_\_\_ on \_\_\_\_\_  
and was amended on \_\_\_\_\_, (if applicable)  
☒ **was filed as PCT international application Number PCT/IL98/00586 on 01 December 1998,**  
and was amended under PCT Article 19 on \_\_\_\_\_.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America listed below and have also identified below, by checking the box, any foreign application(s) for patent or inventor's certificate, or of any PCT international application(s) having a filing date before that of the application(s) on which priority is claimed.

**RIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119:**

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC §119	
			<input type="checkbox"/> YES	<input type="checkbox"/> NO

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or 365(c) of any PCT international application(s) designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT application(s) in the manner provided by the first paragraph of 35, U.S.C. §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56(a) which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

**RIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. §120:**

U.S. APPLICATIONS		STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
<b>60/067,697</b>	<b>4 December 1997</b> ✓			<b>X</b>
PCT APPLICATIONS DESIGNATING THE U.S.				
PCT APPLICATION NO.	PCT FILING DATE	U.S. SERIAL Nos. ASSIGNED (if any)		
<b>PCT/IL98/00586</b>	<b>01 December 1998</b> ✓		<b>X</b>	

**POWER OF ATTORNEY:** As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Peter J. Dehlinger 28,006  
Linda R. Judge 42,702  
Gregory L. Heinkel 44,755

Judy M. Mohr 38,563  
Michael L. Gencarella 44,703

LeeAnn Gortney 37,337  
Michael T. Gabrik 32,896

**OMBINED DECLARATION AND POWER OF ATTORNEY (CONTINUED)**  
**cludes Reference to PCT International Applications)**

ATTORNEY'S DOCKET NO.  
 9325-0007.10

nd Correspondence to: Iota Pi Law Group  
P.O. Box 60850  
Palo Alto, CA 94306

Direct Telephone Calls to:  
 LeeAnn Gorthey  
 (650) 324-0880

1-00	FULL NAME OF INVENTOR	FAMILY NAME <u>Gabizon</u>	FIRST GIVEN NAME <u>Alberto</u>	SECOND GIVEN NAME <u>A.</u>
	RESIDENCE & CITIZENSHIP	CITY <u>Jerusalem</u>	STATE OF FOREIGN COUNTRY <u>Israel ILX</u>	COUNTRY OF CITIZENSHIP <u>IL</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Bernstein Street 56/7</u>	CITY <u>Jerusalem 96920</u>	STATE & ZIP CODE/COUNTRY <u>Israel</u>
2-00	FULL NAME OF INVENTOR	FAMILY NAME <u>Kedar</u>	FIRST GIVEN NAME <u>Eliezer</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Jerusalem</u>	STATE OF FOREIGN COUNTRY <u>Israel ILX</u>	COUNTRY OF CITIZENSHIP <u>IL</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Kadish Luz Street 24/7</u>	CITY <u>Jerusalem 96920</u>	STATE & ZIP CODE/COUNTRY <u>Israel</u>
3-00	FULL NAME OF INVENTOR	FAMILY NAME <u>Barenholz</u>	FIRST GIVEN NAME <u>Yechezkel</u>	SECOND GIVEN NAME
	RESIDENCE & CITIZENSHIP	CITY <u>Jerusalem ILX</u>	STATE OF FOREIGN COUNTRY <u>Israel</u>	COUNTRY OF CITIZENSHIP <u>IL</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS <u>Nave Shannan Street 18</u>	CITY <u>Jerusalem 93707</u>	STATE & ZIP CODE/COUNTRY <u>Israel</u>

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may invalidate the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 201

SIGNATURE OF INVENTOR 202

SIGNATURE OF INVENTOR 203

DATE

DATE

DATE

June 4, 2000

June 4, 2000

June 4, 2000



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: 7.31.00

By: 

Docket No. 9325-0007.10

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

Alberto A. Gabizon, et al.

SERIAL No.: not yet assigned

FILED: June 2, 2000

FOR: **COMBINED CHEMO-IMMUNOTHERAPY WITH  
LIPOSOMAL DRUGS AND CYTOKINES**

EXAMINER: Unknown

ART UNIT: Unknown

**Power of Attorney by Assignee and Certification**  
**Under 37 CFR §3.73(b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

- I, the undersigned, acting on behalf of the Assignee of
- ☒ an undivided share of the entire right, title, and interest
- ☐ the entire right, title and interest

in the above-identified patent application, appoint the attorneys and agents listed below to prosecute this application and transact all business with the U.S. Patent and Trademark Office in connection therewith. This appointment is to the exclusion of the inventor(s) and their attorney(s) and agent(s) in accordance with the provisions of 37 CFR 3.71.

All prior powers of attorney for this application are hereby revoked. The appointed representatives are:

00000000 44995560

7 -

Peter J. Dehlinger, Registration No. 28,006  
Judy M. Mohr, Registration No. 38,563  
LeeAnn Gorthey, Registration No. 37,337  
Linda R. Judge, Registration No. 42,702  
Michael L. Gencarella, Registration No. 44,703  
Michael T. Gabrik, Registration No. 32,896  
Gregory L. Heinkel, Registration No. 44,755

all affiliated with Iota Pi Law Group.

Direct all telephone calls to LeeAnn Gorthey at (650)  
324-0880. Address all correspondence to:

Iota Pi Law Group  
P.O. Box 60850  
Palo Alto, CA 94306  
Telephone: (650) 324-0880

In accordance with 37 CFR 3.73(b), I hereby certify that I am empowered to act on behalf of the Assignee. To the best of my knowledge and belief, title is in the Assignee, as evidenced by the Assignment noted above.

I further declare that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, USC §1001 and that such willful false statements may jeopardize the validity of the this application or any patent resulting therefrom.

**ASSIGNEE:** Hadasit Medical Research Services and Development, Ltd.

Signature: רפאל הופשטיין  
שרותי מחקר רפואי ופיתוח בי"מ

Typed Name: hadasit  
medical research services  
& development ltd.

Title: RAPHAEL HOFSTEIN PH.D.

Date: MANAGING DIRECTOR  
HADASIT MEDICAL RESEARCH  
SERVICE & DEVELOPMENT LTD.

Address: 19/6/2000

0055674-0880

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231, on:

Date: 7.31.00

By: [Signature]

Docket No. 9325-0007.10

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Alberto A. Gabizon, et al.

SERIAL No.: not yet assigned

FILED: June 2, 2000

FOR: COMBINED CHEMO-IMMUNOTHERAPY WITH  
LIPOSOMAL DRUGS AND CYTOKINES

EXAMINER: Unknown

ART UNIT: Unknown

Power of Attorney by Assignee and Certification  
Under 37 CFR §3.73(b)

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, the undersigned, acting on behalf of the Assignee of

☒ an undivided share of the entire right, title, and interest

☐ the entire right, title and interest

in the above-identified patent application, appoint the attorneys and agents listed below to prosecute this application and transact all business with the U.S. Patent and Trademark Office in connection therewith. This appointment is to the exclusion of the inventor(s) and their attorney(s) and agent(s) in accordance with the provisions of 37 CFR 3.71.

All prior powers of attorney for this application are hereby revoked. The appointed representatives are:

7-  
Peter J. Dehlinger, Registration No. 28,006  
Judy M. Mohr, Registration No. 38,563  
LeeAnn Gorthey, Registration No. 37,337  
Linda R. Judge, Registration No. 42,702  
Michael L. Gencarella, Registration No. 44,703  
Michael T. Gabrik, Registration No. 32,896  
Gregory L. Heinkel, Registration No. 44,755

all affiliated with Iota Pi Law Group.

Direct all telephone calls to LeeAnn Gorthey at (650) 324-0880. Address all correspondence to:

Iota Pi Law Group  
P.O. Box 60850  
Palo Alto, CA 94306  
Telephone: (650) 324-0880

In accordance with 37 CFR 3.73(b), I hereby certify that I am empowered to act on behalf of the Assignee. To the best of my knowledge and belief, title is in the Assignee, as evidenced by the Assignment noted above.

I further declare that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, USC §1001 and that such willful false statements may jeopardize the validity of the this application or any patent resulting therefrom.

**ASSIGNEE:** Yisum Research Development Company of the Hebrew University of Jerusalem

Signature: \_\_\_\_\_

Typed Name: Mordehai Perlmutter

Title: Managing Director and CEO

Date: June 19, 2000

Address: 46 Jabotinsky St, P.O.Box 4279, Jerusalem  
91042, Israel